AcuraStem
A patient-based biotechnology company pioneering treatments for neurodegenerative diseases including sporadic amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration.
AcuraStem’s best-in-class disease modeling platform, iNeuroRx, enables the discovery of innovative, effective, and broadly acting treatments.
In September 2023, AcuraStem entered into a license agreement with Takeda to develop and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide for the treatment of ALS.
Latest AcuraStem News & Features
26 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze